STATegics, Inc. is a biopharmaceutical company in Menlo Park, CA, committed to the discovery and development of orally available small molecule modulators of cytokine receptors. The company has identified proprietary small molecules from two preclinical programs and demonstrated superior properties when compared to alternative drugs. STATegics is also developing screening technologies for efficient and rapid identification of small molecules targeting allosteric sites of cytokine receptors, i.e. sites that are unique when compared to the binding sites of the natural ligands. The company is working closely with leading experts and advisors, and is advancing its key programs both internally and through external collaborations.